Navigation Links
Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
Date:1/19/2010

scalating doses and maintenance treatment over a number of years. During the trial investigators will 'challenge' the volunteers with house dust mite allergens to assess the therapeutic effect of Circassia's T-cell vaccine.

"The start of these two studies demonstrates the rapid clinical advance of Circassia's T-cell vaccines. With this further broadening of our portfolio, Circassia now has three development programmes in phase II, targeting some of the most common allergies in the world," said Steve Harris, Circassia's CEO. "We are committed to continuing this rapid pace of development, to ensure we can bring these breakthrough T-cell vaccines to market as soon as possible. We believe that patients can benefit greatly from our ToleroMune allergy therapies, which offer the prospect of simple, convenient and effective treatment while minimising the risk of the severe and sometimes life-threatening side effects associated with many existing immunotherapies."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's cat allergy T-cell vaccine show that short treatment regimes can greatly reduce patients' symptoms, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy T-cell vaccines offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potentia
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
2. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
3. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
4. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
5. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
6. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
7. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
8. Applied Seals North America Extends Global Network With Addition of Distributor in Europe
9. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
10. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
11. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 Juno ... Breakthrough Therapy Designation to the company,s JCAR015 chimeric ... the treatment of relapsed or refractory B-cell acute ... partner, Memorial Sloan Kettering Cancer Center, where Phase ... "The FDA,s action is important news for ...
(Date:11/24/2014)... 24, 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced today that Sergio Traversa , ... LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, ... the Luxe Sunset Bel Air Hotel, which is located ... California . The presentation is scheduled ...
(Date:11/24/2014)... -- GlySens Incorporated announced today that it has been awarded ... Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ... The grant is intended to support human clinical evaluation ... glucose monitoring system.  Final preparations for launch of the ... before the end of 2014. "We are ...
Breaking Medicine Technology:Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Annual NewsMakers in the Biotech Industry Conference on Friday, ... a.m. Eastern Time.  The session may be accessed through ... Investor Relations page.  An archived version of the presentation ...
... CINCINNATI, Oct. 15  "This is a significant decision in ... advocates and the entire pharmaceutical industry," commented Benjamin H. ... an en banc hearing was not necessary and that ... plaintiff,s claim that the diet drug Redux (commonly known ...
Cached Medicine Technology:
(Date:11/26/2014)... For those with a New Year’s resolution to ... classes at the University of Colorado Anschutz Health and ... for. The 45- 60 minute classes have just started and ... fitness club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, ... aimed at fast results , By focusing on low ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. Hill, ... from The American Association of Nurse Practitioners ... nurse practitioners. The Distinguished Preceptorship Award recognizes the ... significant contribution toward increasing the awareness and acceptance ... (AANP) is the largest full-service national professional membership ...
(Date:11/26/2014)... (HealthDay News) -- Vultures have developed highly specialized ways ... eating dead animals, researchers report. The new research ... faces and in the guts of 50 turkey vultures ... the faces of the vultures had more than 500 ... guts, the study found. The findings suggest that ...
(Date:11/26/2014)... to peanut protein in household dust may increase the ... condition eczema, a new study reveals. About 2 ... allergic to peanuts. And severe eczema in infants has ... researchers noted. The new study included 359 infants ... the amount of peanut protein the children were exposed ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Parents need to take ... concussions, an expert warns. Parents must make sure ... standard, Dr. David Dodick, chair of the American Migraine ... Clinic College of Medicine in Scottsdale, Ariz. in an ... release. Any coach involved with teens sports needs ...
Breaking Medicine News(10 mins):Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
... flow may be better conditioned to survive a full-blown ... University of Cincinnati (UC). , In a five-year ... when the heart experiences short periods of stress, either ... activates a protective molecular pathwayknown as JAK-STATthat protects the ...
... WuXi PharmaTech (NYSE:,WX), China,s premier provider of pharmaceutical R&D ... temporarily assume the role of,the Chairman of the Audit ... of the Audit Committee was previously held by Mr. ... his vacation., Mr. Cuong Viet Do has served ...
... drank more heavily than male peers, field study finds ... on-the-scene study of college drinking behavior shows that parties ... while themed parties encourage college women to drink more ... of college drinking have relied largely on individual behavior ...
... - President of cbm, Prof. Allen Foster,announces that cbm ... persons,with disability, not just persons with visual loss., ... Christoffel Blinden,Mission, and Christian Blind Mission, has worked to ... for persons,with visual loss., "The organization has decided ...
... 4 Health Secretary Dr.,Calvin B. Johnson today invited ... exhibit at the Farm Show for free health,screenings, fun ... Body Shop is a fun place for kids and ... running in peak condition," Dr. Johnson said.,"Everyone should stop ...
... International,Associates, Inc, administrator for the HealthShares(TM) Indexes, a ... Funds, today,announced that effective at the opening of ... ARQL ) will replace Coley Pharmaceutical, Inc.,(Nasdaq: ... Index. Coley,Pharmaceutical is being acquired by Pfizer, Inc. ...
Cached Medicine News:Health News:Mini 'stress tests' could help condition heart to survive major attack 2Health News:WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:cbm Expanding its Mandate 2Health News:QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index 2
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: